After beating estimates last quarter by $0.02, rue21
What analysts say:
- Buy, sell, or hold?: Analysts strongly back rue21, with four of six rating it a buy and the remainder rating it a hold. Analysts don't like rue21 as much as competitor Body Central overall. That rating hasn't budged in three months as analysts have remained steady in their opinion of the stock.
- Revenue Forecasts: On average, analysts predict $225.8 million in revenue this quarter. That would represent a rise of 18.8% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.49 per share. Estimates range from $0.48 to $0.50.
What our community says:
CAPS All-Stars are in strong support of the stock, with 91.7% assigning it an "outperform" rating. The majority of Fools agree with the All-Stars, with 74.1% giving it an "outperform" rating. Despite the majority sentiment in favor of rue21, the stock has a middling CAPS rating of three out of five stars.
Rue21's profit has risen year-over-year by an average of 37.2% over the past five quarters.
One final thing: If you want to keep tabs on rue21 movements, and for more analysis on the company, make sure you add it to your Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.